Results 181 to 190 of about 209,258 (305)

Metabolic Reprogramming of T Cells by Dual UCP2 and IL‐17 Blockade Enhances Immunity Against Pancreatic Cancer

Advanced Science, EarlyView.
This study demonstrates that dual UCP2/IL‐17 blockade reprograms T‐cell metabolism to overcome PDAC immunosuppression. Genipin‐mediated UCP2 inhibition enhances CD8⁺ T‐cell IFN‐γ via IL‐12R/STAT4/mTOR signaling and mitochondrial OXPHOS. Combined IL‐17 depletion amplifies Tc1/Th1 responses, reduces MDSCs, and prolongs survival in PDAC models ...
Chuan‐Teng Liu, Chun‐Chieh Yeh, Tsai‐Chen Wu, Chia‐Hsin Lin, Yi‐Ting Kuo, Yoichiro Iwakura, Yuan‐Ji Day, Charles Drake, Vedran Radojcic, Ying‐Chyi Song, Heng‐Hsiung Wu, Hung‐Rong Yen   +11 more
wiley   +1 more source

Lignin-Derived Oligomers as Promising mTOR Inhibitors: Insights from Dynamics Simulations. [PDF]

Int J Mol Sci
Gabellone S, Carotenuto G, Arcieri M, Bottoni P, Sbanchi G, Castrignanò T, Piccinino D, Liverani C, Saladino R.   +8 more
europepmc   +1 more source

mTOR-inhibitors and post-transplant diabetes mellitus: a link still debated in kidney transplantation. [PDF]

Front Med (Lausanne), 2023
Granata S, Mercuri S, Troise D, Gesualdo L, Stallone G, Zaza G.   +5 more
europepmc   +1 more source

Proteogenomic Characterization Reveals Subtype‐Specific Therapeutic Potential for HER2‐Low Breast Cancer

Advanced Science, EarlyView.
Multiomic profiling of HER2‐low breast cancer identifies three proteomic subtypes with distinct therapeutic strategies: endocrine, antiangiogenic, and anti‐HER2 therapies. Genomic and lactate modification landscapes are detailed, providing insights for precise management.
Shouping Xu, Keda Yu, Lei Liu, Qin Wang, Xiaohui Wu, Yihai Chen, Guozheng Li, Xin Zhang, Bo Wei, Zitong Fu, Abiyasi Nanding, Zuxianglan Zhao, Lingbing Yang, Xingda Zhang, Jianyu Wang, Wantong Sun, Yi Hao, Zhongyi Cheng, Xiaojiang Cui, Hao Wu, Da Pang   +20 more
wiley   +1 more source

Fetal cardiac rhabdomyomas susceptible to prenatal treatment with mTOR inhibitors: literature review and proposal of a prenatal management algorithm. [PDF]

Front Med (Lausanne)
Martinez-Garcia A, Tirado-Aguilar OA, Acevedo-Gallegos S, Gallardo-Gaona JM, Velazquez-Torres B, Ramirez-Calvo JA, Camarena-Cabrera DMA, Rodriguez-Sibaja MJ, Lumbreras-Marquez MI, Copado-Mendoza Y.   +9 more
europepmc   +1 more source

Combined Deep Learning and Molecular Modeling Techniques on the Virtual Screening of New mTOR Inhibitors from the Thai Mushroom Database. [PDF]

ACS Omega, 2023
Posansee K, Liangruksa M, Termsaithong T, Saparpakorn P, Hannongbua S, Laomettachit T, Sutthibutpong T.   +6 more
europepmc   +1 more source

ERM Inhibition Confers Ferroptosis Resistance through ROS‐Induced NRF2 Signaling

Advanced Science, EarlyView.
ERM inhibition disrupts ERM‐actin interactions, elevating ROS and triggering KEAP1 degradation, which stabilizes and activates NRF2. Nuclear NRF2 induces cytoprotective genes, notably HMOX1, enhancing redox buffering and suppressing lipid peroxidation to resist erastin‐induced ferroptosis.
Menghao Qiao, Liqun Zhou, Minhua Zhou, Yu Fang, Haiying Mai, Lingbo Cao, Kun Xu, Yuan Sang, Minyi Chen, Jiewei Huang, Peiyi Huang, Zhipeng Yan, Chao Wang, Zhangshuai Dai, Dichun Huang, Ronghan He, Lijuan Pang, Yunmiao Guo, Ting Gang Chew, Junqi Huang   +19 more
wiley   +1 more source

Genetic Evidence Supporting the Repurposing of mTOR Inhibitors for Reducing BMI. [PDF]

Biomedicines
Peng P, Shen F, Peng B, Chen Z, Zhou L, Hao X, Liu Y.   +6 more
europepmc   +1 more source

PI3K/mTOR inhibitors promote G6PD autophagic degradation and exacerbate oxidative stress damage to radiosensitize small cell lung cancer. [PDF]

Cell Death Dis, 2023
Deng H, Chen Y, Wang L, Zhang Y, Hang Q, Li P, Zhang P, Ji J, Song H, Chen M, Jin Y.   +10 more
europepmc   +1 more source

Targeting mTOR: up-to-date mTOR inhibitors

Biorganic and Medicinal Chemistry Reports, 2019
Banu Kilic, Meryem Temiz-Resitoglu, Seyhan Sahan Firat   +2 more
openaire   +1 more source